Skip to search formSkip to main contentSkip to account menu

AOD 9604

Known as: somatostatin (177-191), Tyr-, somatostatin (177-191), tyrosyl-, AOD-9604 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Peptide FragmentsSomatostatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.
BACKGROUND To investigate the effects of AOD9604 intra-articular injections with or without hyaluronic acid (HA) in a collagenase… 
2014
2014
Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions
With the growing availability of mature systems and strategies in biotechnology and the continuously expanding knowledge of… 
2014
2014
Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health
Background: AOD9604 is the C-terminal fragment (Tyr-hGH177-191) of human growth hormone (hGH). Early stage studies with AOD9604… 
Review
2014
Review
2014
Identification of peptide and protein doping related drug compounds confiscated in Denmark between 2007-2013
Abstract We present an overview of protein and peptide compounds confiscated in Denmark from late 2007 till late 2013 together… 
Review
2007
Review
2007
[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
This review summarizes data on currently used antiobesity drugs and new compounds under clinical development. Three antiobesity… 
Review
2006
Review
2006
Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors
The serotonin, norepinephrine, dopamine, and endocannabinoid systems, as well as a host of other systems, mediate hunger and… 
2005
2005
The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study
Review
2004
Review
2004
AOD-9604 Metabolic.
Metabolic is developing AOD-9604 for the potential treatment of obesity. By February 2002, phase IIa trials were underway. 
2001
2001
The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice.
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and… 
2001
2001
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)